A Randomized Phase II b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis-Reference-Cited by-同舟云学术

A Randomized Phase II b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis

Published:2017-12-27 Issue:1 Volume:70 Page:49-59
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Weinblatt Michael E.¹,McInnes Iain B.²,Kremer Joel M.³,Miranda Pedro⁴,Vencovsky Jiri⁵,Guo Xiang⁶,White Wendy I.⁶,Ryan Patricia C.⁶,Godwood Alex⁷,Albulescu Marius⁷,Close David⁷,Burmester Gerd R.⁸

Affiliation:

1. Brigham and Women's Hospital Boston Massachusetts

2. Glasgow Biomedical Research Centre Glasgow UK

3. Center for Rheumatology Albany New York

4. Universidad de Chile and Hospital San Juan de Dios Santiago Chile

5. Institute of Rheumatology Charles University Prague Czech Republic

6. MedImmune Gaithersburg Maryland

7. MedImmune Cambridge UK

8. Charité–University Medicine Berlin Free University of Berlin, and Humboldt University of Berlin Berlin Germany

Funder

AstraZeneca

MedImmune

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.40323

Reference31 articles.

1. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis

2. The Pathogenesis of Rheumatoid Arthritis

3. Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis

4. Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis

5. Plasma GM‐CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy;Fiehn C;Z Rheumatol,1992

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum GM-CSF level is a predictor of treatment response to tocilizumab in rheumatoid arthritis patients: a prospective observational cohort study;Arthritis Research & Therapy;2024-07-12

2. GMCSF: More an Inflammatory Immune ‘Cytokine’ Than a Growth Factor;Indian Journal of Rheumatology;2024-06-23

3. Non-TNF biologics and their biosimilars in rheumatoid arthritis;Expert Opinion on Biological Therapy;2024-05-22

4. Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options;Drugs;2024-03

5. Skin involvement in other autoimmune diseases;The Rose and Mackay Textbook of Autoimmune Diseases;2024